Free Trial
NASDAQ:CALC

CalciMedica (CALC) Stock Price, News & Analysis

CalciMedica logo
$1.76 -0.04 (-2.22%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.76 +0.00 (+0.28%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CalciMedica Stock (NASDAQ:CALC)

Key Stats

Today's Range
$1.74
$1.83
50-Day Range
$1.48
$2.08
52-Week Range
$1.43
$6.02
Volume
11,759 shs
Average Volume
45,756 shs
Market Capitalization
$24.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

CalciMedica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

CALC MarketRank™: 

CalciMedica scored higher than 55% of companies evaluated by MarketBeat, and ranked 659th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CalciMedica has only been the subject of 1 research reports in the past 90 days.

  • Read more about CalciMedica's stock forecast and price target.
  • Earnings Growth

    Earnings for CalciMedica are expected to decrease in the coming year, from ($2.21) to ($2.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CalciMedica is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CalciMedica is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CalciMedica has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CalciMedica's valuation and earnings.
  • Percentage of Shares Shorted

    1.09% of the float of CalciMedica has been sold short.
  • Short Interest Ratio / Days to Cover

    CalciMedica has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CalciMedica has recently decreased by 35.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CalciMedica does not currently pay a dividend.

  • Dividend Growth

    CalciMedica does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.09% of the float of CalciMedica has been sold short.
  • Short Interest Ratio / Days to Cover

    CalciMedica has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CalciMedica has recently decreased by 35.43%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CalciMedica has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for CalciMedica this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CALC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CalciMedica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about CalciMedica's insider trading history.
Receive CALC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter.

CALC Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
CalciMedica Inc. Common Stock
See More Headlines

CALC Stock Analysis - Frequently Asked Questions

CalciMedica's stock was trading at $3.54 at the beginning of 2025. Since then, CALC shares have decreased by 50.3% and is now trading at $1.76.
View the best growth stocks for 2025 here
.

CalciMedica, Inc. (NASDAQ:CALC) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07.

Top institutional shareholders of CalciMedica include Stonepine Capital Management LLC (2.63%), Wealthedge Investment Advisors LLC (0.78%), Cambridge Investment Research Advisors Inc. (0.17%) and 180 Wealth Advisors LLC (0.12%). Insiders that own company stock include Sanderling Venture Partners Vi, Robert N Wilson, Eric W Roberts and A Rachel Leheny.
View institutional ownership trends
.

Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM).

Company Calendar

Last Earnings
5/14/2025
Today
5/27/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALC
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$20.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+922.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.36 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
1.24

Miscellaneous

Free Float
7,880,000
Market Cap
$24.59 million
Optionable
No Data
Beta
1.24
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CALC) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners